Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Accumulated Expenses data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 212.78% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 212.78%, while the annual FY2025 figure was $3.7 million, 212.78% up from the prior year.
  • Accumulated Expenses reached $3.7 million in Q4 2025 per LCTX's latest filing, up from $486000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $21.0 million in Q1 2022 and bottomed at $349000.0 in Q3 2023.
  • Average Accumulated Expenses over 5 years is $3.8 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: soared 2025.51% in 2022, then crashed 98.08% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $1.6 million in 2021, then skyrocketed by 45.33% to $2.4 million in 2022, then plummeted by 53.95% to $1.1 million in 2023, then increased by 9.12% to $1.2 million in 2024, then soared by 212.78% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $3.7 million in Q4 2025, $486000.0 in Q3 2025, and $2.2 million in Q2 2025.